Heart failure therapy: the fifth card

Link to article at PubMed

Eur Heart J Suppl. 2023 Apr 21;25(Suppl B):B140-B143. doi: 10.1093/eurheartjsupp/suad099. eCollection 2023 Apr.


The 2021 European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic heart failure (HF) have abandoned the sequential approach for optimal drug therapy and propose four drug classes (enzyme inhibitors conversion agents, angiotensin receptor antagonists, beta-blockers, and sodium-glucose cotransporter inhibitors 2) to be initiated and titrated in all patients with an ejection fraction <35%. This new approach offers advantages such as rapid introduction and titration, better tolerability, and early instrumental re-evaluation. In the VICTORIA study, the molecule vericiguat, a soluble guanylate cyclase activator, was shown to reduce the composite outcome of death from cardiovascular causes and first hospitalization for HF in a high-risk population. An additional randomized clinical trial (VICTOR) is ongoing to evaluate the efficacy and safety of vericiguat in a population with HF on optimized therapy and with no recent episodes of stabilization.

PMID:37091657 | PMC:PMC10120986 | DOI:10.1093/eurheartjsupp/suad099

Leave a Reply

Your email address will not be published. Required fields are marked *